Routinely collected general practice data aids identification of people with hyperglycaemia and metabolic syndrome

Diabetic Medicine

Volumn 23, Issue 9, 2006, Pages 996-1002

  Heldgaard, P E ^a,b   Griffin, S J ^c  

^a Ørum Health Centre   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

General practice; Metabolic syndrome; Risk score; Screening; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; STEROID;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; DENMARK; FAMILY HISTORY; FEMALE; GENDER; GENETIC SUSCEPTIBILITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RISK ASSESSMENT; RURAL AREA; SENSITIVITY AND SPECIFICITY; SMOKING HABIT; STATISTICAL MODEL; STEROID THERAPY;

ADULT; AGED; BODY CONSTITUTION; DIABETES MELLITUS, TYPE 2; EPIDEMIOLOGIC METHODS; FAMILY PRACTICE; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 33747512854     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01929.x     Document Type: Article

References (33)

1. American Diabetes Association. Screening for type 2 diabetes. Position statement. Diabetes Care 2004; 27: S11-S14.
2. Diabetes UK. Position statement. Early identification of people with Type 2 diabetes. 2002: 1-8. Available from: http://www.diabetes.org.uk/infocentre/ state/downloads/earlyid.doc (accessed 12 April 2004).
3. Burke JP, Williams K, Narayan KM, Leibson C, Haffner SM, Stern MP. A population perspective on diabetes prevention: whom should we target for preventing weight gain? Diabetes Care 2003; 26: 1999-2004.
4. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. Br Med J 2001; 322: 986-988.
5. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004; 140: 689-699.
6. Cowie CC, Harris MI, Eberhardt MS. Frequency and determinants of screening for diabetes in the US. Diabetes Care 1994; 17: 1158-1163.
7. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in non-diabetic European men and women. Arch Intern Med 2004; 164: 1066-1076.
8. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Hanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
9. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
10. Herman WH, Smith PJ, Thompson TJ, Engelgau MM, Aubert RE. A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes. Diabetes Care 1995; 18: 382-387.
11. Ruige JB, de Neeling JN, Kostense PJ, Bouter LM, Heine RJ. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care 1997; 20: 491-496.
12. Baan CA, Ruige JB, Stolk RP, Witteman JC, Dekker JM, Heine RJ, Feskens EJ. Performance of a predictive model to identify undiagnosed diabetes in a health-care setting. Diabetes Care 1999; 22: 213-219.
13. Tuomilehto J, Lindstrom J, for The Finnish Diabetes Association. Diabetes Test. 2001. Available from: http://www.diabetes.fi/svenska/information/test/ index.htm (accessed 12 April 2004).
14. Shaw C, Abrams K, Marteau TM. Psychological impact of predicting individuals' risks of illness: a systematic review. Soc Sci Med 1999; 49: 1571-1598.
15. Marteau TM, Kinmonth AL, Thompson S, Pyke S. The psychological impact of cardiovascular screening and intervention in primary care: a problem of false reassurance? British Family Heart Study Group. Br J Gen Pract 1996; 46: 577-582.
16. Spijkerman A, Griffin S, Dekker J, Nijpels G, Wareham NJ. What is the risk of mortality for people who are screen positive in a diabetes screening programme but who do not have diabetes on biochemical testing? Diabetes screening programmes from a public health perspective. J Med Screen 2002; 9: 187-190.
17. Park PJ, Griffin SJ, Sargeant L, Wareham NJ. The performance of a risk score in predicting undiagnosed hyperglycemia. Diabetes Care 2002; 25: 984-988.
18. Spijkerman AM, Yuyun MF, Griffin SJ, Dekker JM, Nijpels G, Wareham NJ. The performance of a risk score as a screening test for undiagnosed hyperglycemia in ethnic minority groups: data from the 1999 health survey for England. Diabetes Care 2004; 27: 116-122.
19. Heldgaard PE, Olivarius NF, Hindsberger C, Henriksen JE. Impaired fasting glycaemia resembles impaired glucose tolerance with regard to cardiovascular risk factors: population-based, cross-sectional study of risk factors for cardiovascular disease. Diabet Med 2004; 21: 363-370.
20. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. WHO/NCD/NCS/99.2. Geneva, Switzerland: World Health Organization, Department of Non-Communicable Disease Surveillance, 1999.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
22. Altman DG, Machin D, Bryant TN, Gardner MJ. Statistics with Confidence, 2nd edn. London: BMJ Books, 2000.
23. Glumer C, Jorgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish population: The Inter99 Study. Diabetes Care 2003; 26: 2335-2340.
24. Segal L, Dalton AC, Richardson J. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus. Health Promotion Int 1998; 13: 197-209.
25. Jones A, Cronin PA, Bowen M. Comparison of risk factors for coronary heart disease among attenders and non-attenders at a screening programme. Br J Gen Pract 1993; 43: 375-377.
26. Schousboe K, Henriksen JE, Kyvik KO, Sorensen TI, Hyltoft PP. Reproducibility of S-insulin and B-glucose responses in two identical oral glucose tolerance tests. Scand J Clin Lab Invest 2002; 62: 623-630.
27. Mooy JM, Grootenhuis PA, de Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ. Intra-individual variation of glucose, specific insulin and pro-insulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996; 39: 298-305.
28. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-240.
29. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). Br Med J 2001; 322: 15-18.
30. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of type 2 diabetes in general practice. Diabetes Metab Res Rev 2000; 16: 164-171.
31. Little P. GP documentation of obesity: what does it achieve? Br J Gen Pract 1998; 48: 890-894.
32. Jeffery RW. Bias in reported body weight as a function of education, occupation, health and weight concern. Addict Behav 1996; 21: 217-222.
33. Westin S, Heath I. Thresholds for normal blood pressure and serum cholesterol. Br Med J 2005; 330: 1461-1462.